PriceSensitive

Numinus (TSX:NUMI) expands ketamine therapy

Health Care, Psychedelics
TSX:NUMI
22 September 2022 13:34 (EDT)
Numinus Wellness - Founder & CEO, Payton Nuquvest

Source: LinkedIn

Numinus Wellness (NUMI) announced the opening of a new clinic in Montreal that will replace an existing downtown clinic.

The new site is in the Plateau neighbourhood and will have an expanded capacity to offer ketamine treatments, including a wider assortment of ketamine-assisted therapy options.

Jason Lapensee, Numinus Senior Vice President of Clinical Operations, commented,

“There is significant research showing ketamine can be highly effective in treating depression, addiction, trauma and anxiety, and other common mental health disorders.”

Expanded services will include different administrations of ketamine such as Spravato, intramuscular, lozenge, and nasal spray, along with options in treatment length and session type.

The company’s current offering includes a six-week ketamine-assisted therapy program for indications including depression, addiction, trauma, and anxiety.

 New services will include the option to access ketamine as a standalone treatment to allow clients to use it before ketamine-assisted therapy, as an emergency antidepressant, or with therapy from an external health provider.

 Additionally, Numinus will continue to support access for clients in need through the federal Special Access Program with areas designated for psilocybin- and MDMA-assisted therapies.

Payton Nyquvest, Numinus Founder and CEO stated,

“Expanding our services here is another important step towards improving access to best-in-class and innovative mental healthcare in Quebec while continuing to expand our clientele and market presence.”

Numinus Wellness Inc. (NUMI) is down 3.64 per cent, trading at $0.26 per share as of 1:27 p.m. ET.


Related News